-
泛昔洛韋
- names:
Famciclovir
- CAS號(hào):
104227-87-4
MDL Number: MFCD00866964 - MF(分子式): C14H19N5O4 MW(分子量): 321.33
- EINECS:630-411-6 Reaxys Number:
- Pubchem ID:3324 Brand:BIOFOUNT
| 貨品編碼 | 規(guī)格 | 純度 | 價(jià)格 (¥) | 現(xiàn)價(jià)(¥) | 特價(jià)(¥) | 庫(kù)存描述 | 數(shù)量 | 總計(jì) (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM000717-100mg | 100mg | 99.74% | ¥ 1251.00 | ¥ 1251.00 | 2-3天 | ¥ 0.00 | ||
| YZM000717-50mg | 50mg | 99.74% | ¥ 696.15 | ¥ 696.15 | 2-3天 | ¥ 0.00 |
- 大包裝詢(xún)價(jià) 提供各種包裝,敬請(qǐng)垂詢(xún)
- 收藏商品 商品點(diǎn)評(píng) 加入購(gòu)物車(chē) 立即購(gòu)買(mǎi)
| 中文別名 | 泛昔洛韋(104227-87-4);法昔洛為; 法昔洛韋;1,3-丙二醇,2-(2-(2-氨基-9H-嘌呤-9-基)乙基)-二乙酸酯(酯); 9-(4-乙酰氧基-3-(乙酰氧基甲基)丁-1-基)-2-氨基嘌呤;BRL 42810;BRL-42810;BRL42810; |
| 英文別名 | Famciclovir(104227-87-4);BRL-42810;BRL 42810;BRL42810;2-(2-(2-Amino-9H-purin-9-yl)ethyl)propane-1,3-diyl diacetate; 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate ester; 2-[2-(2-Amino-9H-purin-9-yl)ethyl]-1,3-propanediol Diacetate; Famciclovir; Amciclovir; Famciclover; FaMtrex; FaMciclovir API; Famvir; famcyclovir; FCV; FaMcivir;1,3-Propanediol, 2-(2-(2-amino-9H-purin-9-yl)ethyl)-, diacetate (ester) ;9-(4-acetoxy-3-(acetoxymethyl)but-1-yl)-2-aminopurine;famciclovir;Famvir; |
| CAS號(hào) | 104227-87-4 |
| Inchi | InChI = 1S / C14H19N5O4 / c1-9(20)22-6-11(7-23-10(2)21)3-4-19-8-17-12-5-16-14(15)18- 13(12)19 / h5,8,11H,3-4,6-7H2,1-2H3,(H2,15,16,18) |
| InchiKey | GGXKWVWZWMLJEH-UHFFFAOYSA-N |
| 分子式 Formula | C14H19N5O4 |
| 分子量 Molecular Weight | 321.33 |
| 溶解度Solubility | 生物體外In Vitro:DMSO溶解度≥ 100 mg/mL(311.21 mM)H2O : 50 mg/mL(155.60 mM;Need ultrasonic)*"≥" means soluble可溶, but saturation unknown溶解度未知. |
| 性狀 | 白色晶體灰白色固體粉末,Power |
| 儲(chǔ)藏條件 Storage conditions | -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
泛昔洛韋(104227-87-4,Famciclovir,BRL 42810)毒理性質(zhì):
Famciclovir has been associated with a low rate of serum aminotransferase elevations during oral therapy. In pooled analyses of patients on long term suppressive therapy, 3.2% of famciclovir vs 1.5% of placebo recipients had ALT elevations above twice normal. The elevations were transient and asymptomatic and resolved even without dose modification. Since approval, cases of cholestatic jaundice have been reported to the sponsor, but there have been no published cases. Thus, clinically apparent liver disease due to famciclovir must be rare if it occurs at all.
Likelihood score: E (unlikely cause of clinically apparent liver injury).
泛昔洛韋(104227-87-4,Famciclovir,BRL 42810)實(shí)驗(yàn)注意事項(xiàng):
1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡,穿戴防護(hù)服和口罩,佩戴手套,避免與皮膚接觸。
2.實(shí)驗(yàn)過(guò)程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生,必要時(shí)實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對(duì)實(shí)驗(yàn)人員造成傷害
3.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類(lèi)存儲(chǔ),并交于專(zhuān)業(yè)生物廢氣物處理公司處理,以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tags:泛昔洛韋試劑,泛昔洛韋雜質(zhì),泛昔洛韋合成,泛昔洛韋中間體,泛昔洛韋密度,泛昔洛韋溶解度,泛昔洛韋旋光度,泛昔洛韋閃點(diǎn),泛昔洛韋購(gòu)買(mǎi),
| 產(chǎn)品說(shuō)明 | 泛昔洛韋(104227-87-4,Famciclovir,BRL 42810)是一種鳥(niǎo)嘌呤類(lèi)似物抗病毒藥物,泛昔洛韋用于治療各種皰疹病毒感染C50值. |
| Introduction | 泛昔洛韋(104227-87-4,Famciclovir,BRL 42810)is a guanine analogue antiviral drug used for the treatment of various herpesvirus infections.IC50 Value: Refer to penciclovir |
| Application1 | Famciclovir(BRL 42810)是鳥(niǎo)嘌呤類(lèi)似物,具有抗皰疹病毒活性。 |
| Application2 | 泛昔洛韋(Famvir)是鳥(niǎo)嘌呤類(lèi)似物抗病毒藥物,用于治療各種皰疹病毒感染,最常見(jiàn)的是帶狀皰疹(帶狀皰疹)。 它是噴昔洛韋的前藥形式,具有改善的口服生物利用度。 |
| Application3 |
泛昔洛韋(104227-87-4,Famciclovir,BRL 42810)藥理學(xué):
1、泛昔洛韋是一種前藥,它經(jīng)歷了快速生物轉(zhuǎn)化為活性抗病毒藥噴昔洛韋。Penciclovir是一種抗病毒藥物,對(duì)1型單純皰疹病毒(HSV-1)和2型單純皰疹病毒(HSV-2)和水痘帶狀皰疹病毒(VZV)具有抑制活性。因此,皰疹病毒DNA的合成和復(fù)制被選擇性抑制。
2、泛昔洛韋是抗病毒藥物噴昔洛韋的二乙?;?-脫氧前藥類(lèi)似物??诜何袈屙f可在體內(nèi)轉(zhuǎn)化為噴昔洛韋三磷酸,后者對(duì)皰疹病毒具有活性,包括單純皰疹1和2和水痘帶狀皰疹。該試劑通過(guò)競(jìng)爭(zhēng)性干擾DNA聚合酶來(lái)抑制病毒DNA的復(fù)制。
3、泛昔洛韋是核酸合成抑制劑可以抑制細(xì)胞產(chǎn)生DNA或RNA的化合物。
4、泛昔洛韋是抗病毒劑,可以用于預(yù)防或治療病毒性疾病的藥物。它們可能發(fā)揮作用的方式包括通過(guò)抑制病毒DNA聚合酶來(lái)防止病毒復(fù)制。與特定的細(xì)胞表面受體結(jié)合并抑制病毒滲透或脫殼;抑制病毒蛋白質(zhì)合成;或阻止病毒組裝的后期。泛昔洛韋是一種核苷類(lèi)似物和抗病毒劑,用于治療帶狀皰疹和單純皰疹病毒感染。泛昔洛韋與治療期間血清中度至中度血清ALT升高率低相關(guān),但與臨床上明顯的肝損傷無(wú)關(guān)。
5、泛昔洛韋,也稱(chēng)為泛昔洛韋或BRL-42810,屬于稱(chēng)為嘌呤和嘌呤衍生物的有機(jī)化合物。這些是含有芳香雜環(huán)化合物的嘌呤部分,其上形成有嘧啶稠合到環(huán)型圈咪唑環(huán)。
6、泛昔洛韋是一種用于治療急性帶狀皰疹(帶狀皰疹)的藥物。還用于治療或抑制免疫活性患者的生殖器皰疹復(fù)發(fā)和HIV感染患者的復(fù)發(fā)性皮膚粘膜單純皰疹感染。泛昔洛韋以固體存在,微溶(在水中)和極弱的酸性(基本上是中性)化合物(基于其pKa)。在多種生物流體(如尿液和血液)中檢測(cè)到泛昔洛韋。在細(xì)胞內(nèi),泛昔洛韋主要位于細(xì)胞質(zhì)中。
| 警示圖 | |
| 危險(xiǎn)性 | warning |
| 危險(xiǎn)性警示 | Not available |
| 安全聲明 | H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對(duì)身體有害 |
| 安全防護(hù) | P264處理后徹底清洗+P280戴防護(hù)手套/穿防護(hù)服/戴防護(hù)眼罩/戴防護(hù)面具+P305如果進(jìn)入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡(如果有)并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護(hù)理 |
| 備注 | 實(shí)驗(yàn)過(guò)程中防止吸入、食入,做好安全防護(hù) |
泛昔洛韋(104227-87-4,Famciclovir,BRL 42810)危害標(biāo)識(shí):
| 象形圖 | ![]() |
| 信號(hào) | Danger |
| GHS危險(xiǎn)說(shuō)明 | Aggregated GHS information provided by 4 companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
| H319 (50%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] | |
| H341 (25%): Suspected of causing genetic defects [Warning Germ cell mutagenicity] | |
| H351 (25%): Suspected of causing cancer [Warning Carcinogenicity] | |
| H360 (50%): May damage fertility or the unborn child [Danger Reproductive toxicity] | |
| Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. | |
| 防范說(shuō)明代碼 | P201, P202, P264, P280, P281, P305+P351+P338, P308+P313, P337+P313, P405, and P501 |
| (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| Harrell AW, Wheeler SM, Pennick M, Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6 beta-hydroxylation of testosterone in human liver microsomes. Drug Metab Di |
| Perry CM, Wagstaff AJ. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs. 1995 Aug;50(2):396-415. |
| Trépo C, Jezek P, Atkinson G, Famciclovir in chronic hepatitis B: results of a dose-finding study. J Hepatol. 2000 Jun;32(6):1011-8. |
| Filer CW, Ramji JV, Allen GD, Metabolic and pharmacokinetic studies following oral administration of famciclovir to the rat and dog. Xenobiotica. 1995 May;25(5):477-90. |
| Wutzler P, Ulbricht A, F?rber I. Antiviral efficacies of famciclovir, valaciclovir, and brivudin in disseminated herpes simplex virus type 1 infection in mice. Intervirology. 1997;40(1):15-21. |
泛昔洛韋(104227-87-4,Famciclovir,BRL 42810)參考文獻(xiàn):
1.Interventions for prevention of herpes simplex labialis (cold sores on the lips).
Chi CC1, Wang SH, Delamere FM, Wojnarowska F, Peters MC, Kanjirath PP. Cochrane Database Syst Rev. 2015 Aug 7;8:CD010095. doi: 10.1002/14651858.CD010095.pub2.
BACKGROUND: Herpes simplex labialis (HSL), also known as cold sores, is a common disease of the lips caused by the herpes simplex virus, which is found throughout the world. It presents as a painful vesicular eruption, forming unsightly crusts, which cause cosmetic disfigurement and psychosocial distress. There is no cure available, and it recurs periodically.
2.Treatment of Abdominal Segmental Hernia, Constipation, and Pain Following Herpes Zoster with Paravertebral Block.
Kim S1, Jeon Y. Pain Physician. 2015 Sep-Oct;18(5):E927-9.
Herpes zoster (HZ) most commonly occurs in elderly patients and involves sensory neurons resulting in pain and sensory changes. Clinically significant motor deficits and visceral neuropathies are thought to be relatively rare. A 72-year-old man presented with abdominal segmental hernia, constipation, and pain following HZ in the left T9-10 dermatome. Sixteen days before presentation, he had developed a painful herpetic rash in the left upper abdominal quadrant. Approximately 10 days after the onset of the rash, constipation occurred and was managed with daily oral medication with bisacodyl 5 mg. In addition, 14 days after the onset of HZ, the patient noticed a protrusion of the left upper abdominal wall. Abdominal x-ray, ultrasound of the abdomen, and electrolyte analysis showed no abnormalities. General physical examination revealed a reducible bulge in his left upper quadrant and superficial abdominal reflexes were diminished in the affected region.
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
胞爬片免疫組化染色.png)
怎么做細(xì)胞爬片免疫組化染色實(shí)驗(yàn)
細(xì)胞爬片免疫組化染色,是通過(guò)細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi),細(xì)胞在玻片上生長(zhǎng),主要用于組織學(xué),免疫組織化學(xué)...
2020/7/20 22:04:33

提取病毒RNA的實(shí)驗(yàn)方法
提取病毒RNA方法分別有:異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26

9月開(kāi)學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55

Waxfilm 實(shí)驗(yàn)室封口膜:技術(shù)與國(guó)際市場(chǎng)的雙重突破
在實(shí)驗(yàn)室耗材領(lǐng)域,封口膜是保障實(shí)驗(yàn)準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來(lái),Waxfilm?實(shí)驗(yàn)室封口膜憑借其卓...
2025/5/13 13:03:40

Waxfilm實(shí)驗(yàn)室封口膜的5大突破
Waxfilm實(shí)驗(yàn)室封口膜作為生物功能膜領(lǐng)域的國(guó)產(chǎn)技術(shù)突破和品牌突破,是生物領(lǐng)域中國(guó)技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07

各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)
微流控芯片鍵合:目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接,每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...
2023/7/28 10:43:09
材料.jpg)
新一代微流控鍵合解決方案
微流控鍵合解決方案:微流控芯片制造的一個(gè)重要環(huán)節(jié),也是最容易被忽視的--芯片鍵合。其中一個(gè)重要因素是:微流控...
2023/7/27 12:44:28
驗(yàn)動(dòng)物圖.png)
熒光素鉀鹽使用說(shuō)明
D-熒光素鉀鹽(K+)設(shè)計(jì)用于體外和體內(nèi)生物發(fā)光測(cè)定。D-熒光素的質(zhì)量和純度對(duì)于獲得良好和可重復(fù)的結(jié)果至關(guān)重...
2023/7/20 11:05:11

如何選BSA(牛血清白蛋白)
如何選BSA(牛血清白蛋白):牛血清白蛋白(BSA)有多種形式,如何選擇適合自己的牛血清白蛋白(BSA)是一...
2023/2/14 13:09:18

牛血清白蛋白(BSA)常見(jiàn)問(wèn)題
牛血清白蛋白(BSA)常見(jiàn)問(wèn)題:牛血清白蛋白(BSA)在實(shí)驗(yàn)室中是通用的,可用于蛋白質(zhì)印跡、細(xì)胞組織培養(yǎng)、P...
2022/10/19 9:39:51



購(gòu)物車(chē) 



